Preben H. Olesen - Concepedia

Author

Preben H. Olesen

Also Known As

P H Olesen, P. H. OLESEN, P. Olesen, P.H Olesen, P.H. Olesen, Preben H Olesen, Preben H. Olesen, Preben Houlberg Olesen, Preben Olesen

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Novo Nordisk (Denmark)Eli Lilly (United States)University of Copenhagen Pfizer (United States)

About

Preben H. Olesen is an author at Novo Nordisk (Denmark) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	1K
2	Natural Sciences	10	10	691
3	Health Sciences	3	3	150
4	Engineering	2	2	52
5	Social Sciences	1	1	54

Preben H. Olesen

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Small-molecule agonists for the glucagon-like peptide 1 receptor Lotte Bjerre Knudsen, Dan Kiel, Min Teng, Proceedings of the National Academy of Sciences Rat PancreasGlycobiologyInsulin SignalingGastrointestinal Peptide HormoneMolecular Pharmacology	2007	223
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines Per Sauerberg, Preben H. Olesen, Susanne Nielsen, Journal of Medicinal Chemistry	1992	162
Synthesis and in Vitro Characterization of 1-(4-Aminofurazan-3-yl)-5-dialkylaminomethyl-1<i>H</i>-[1,2,3]triazole-4-carboxylic Acid Derivatives. A New Class of Selective GSK-3 Inhibitors Preben H. Olesen, Anders R. Sørensen, Birgitte Ursø, Journal of Medicinal Chemistry Vitro CharacterizationGlycobiologyPharmacotherapyPharmaceutical ChemistryMedicinal Chemistry	2003	151
Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. H E Shannon, Frank P. Bymaster, David O. Calligaro, Journal of Pharmacology and Experimental Therapeutics Molecular PharmacologyM1 ReceptorsMedicineG Protein-coupled ReceptorPhysiology	1994	107
Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease Frank P. Bymaster, Celia A. Whitesitt, Harlan E. Shannon, Drug Development Research Neurochemical BiomarkersPharmacotherapyExperimental PharmacologyMolecular PharmacologyAlzheimer's Disease	1997	104
Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane Frank P Bymaster, Harlan E. Shannon, Kurt Rasmussen, European Journal of Pharmacology Medicinal ChemistryPsychoactive DrugPsychiatryMedicinePsychopharmacology	1998	65
Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors Lars Nærum, Leif Nørskov‐Lauritsen, Preben H. Olesen Bioorganic & Medicinal Chemistry Letters Scaffold HoppingBiochemistryProtein AssemblyNatural SciencesOptimization Towards Libraries	2002	64
Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor Min Teng, Michael D. Johnson, Christine K. Thomas, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMolecular PhysiologySignal TransductionBiochemistryG Protein-coupled Receptor	2007	63
Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). Frank P. Bymaster, D T Wong, Charles H. Mitch, Journal of Pharmacology and Experimental Therapeutics	1994	62
Potential role of muscarinic receptors in schizophrenia Frank P. Bymaster, Harlan E. Shannon, Kurt Rasmussen, Life Sciences PsychiatryPsychopharmacologySchizophreniaNeuropharmacologyNeuroscience	1999	54

Page 1